UNSPSC 51112018: Vatalanib succinate

This classification denotes a tyrosine kinase inhibitor with the molecular structure C20H15CLN4.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, V5FUB77031 chemically known as 1-phthalazinamine, n-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1), but more commonly known as vatalanib succinate, which bears US NIH Compound Identifier 151193. European Medicines Agency schedules Vatalanib succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32570.

UNSPSC 51112018 Vatalanib succinate is a Commodity code representing pharmaceutical active ingredients and finished products procured by state and local health systems, departments of corrections, and multistate purchasing cooperatives for hospital formularies, institutional pharmacy dispensing, and inmate healthcare programs. State and local government purchasing under this code centers on generic pharmaceuticals and over-the-counter products sourced through established wholesaler networks, with vendors required to demonstrate FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and pricing flexibility across multiple net-price and WAC-minus structures. Issuing bodies include state departments of health and human services, state departments of corrections, county health departments, city health agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions to achieve volume pricing and standardized product access. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents a common issuing model, where a lead state administers cooperative contracts on behalf of participating states and local entities.

The code shows concentrated recent activity in the upper Midwest and Pacific Northwest. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued a Request for Proposal (RFP S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. MMCAP requires vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), supply products with specific National Drug Codes and SKUs, and accept a 3 percent administrative fee on all purchases. The contract term runs two years from an effective date of July 1, 2026, with optional extensions at MMCAP's sole discretion. Evaluation criteria weight price competitiveness at 75 percent, with remaining points allocated to fixed pricing stability, administrative compliance, EDI capability, and acceptance of the administrative fee structure.